RS58141B1 - Anti-cxcr3 antitela - Google Patents

Anti-cxcr3 antitela

Info

Publication number: RS58141B1
Authority: RS; Serbia
Prior art keywords: cxcr3 antibodies; cxcr3; antibodies
Prior art date: 2012-01-20

Application number

RS20181422A

Other languages

English (en)

Inventor

Michele Youd

Jennifer Tedstone

Tracey Lodie

Karen B Carter

Timothy D Connors

Jason Robert Pinckney

Elizabeth Masterjohn

Ruiyin Chu

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-20

Filing date

2013-01-18

Publication date

2019-02-28

2013-01-18 Application filed by Genzyme Corp filed Critical Genzyme Corp

2019-02-28 Publication of RS58141B1 publication Critical patent/RS58141B1/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

RS20181422A 2012-01-20 2013-01-18 Anti-cxcr3 antitela RS58141B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261588936P	2012-01-20	2012-01-20
PCT/US2013/022280 WO2013109974A2 (en)	2012-01-20	2013-01-18	Anti-cxcr3 antibodies
EP13702548.2A EP2804878B1 (en)	2012-01-20	2013-01-18	Anti-cxcr3 antibodies

Publications (1)

Publication Number	Publication Date
RS58141B1 true RS58141B1 (sr)	2019-02-28

Family

ID=47633576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20181422A RS58141B1 (sr)	2012-01-20	2013-01-18	Anti-cxcr3 antitela

Country Status (27)

Country	Link
US (4)	US8865870B2 (sr)
EP (1)	EP2804878B1 (sr)
JP (3)	JP6352812B6 (sr)
KR (2)	KR102073034B1 (sr)
CN (1)	CN104507967B (sr)
AR (1)	AR090056A1 (sr)
AU (1)	AU2013209492B2 (sr)
BR (1)	BR112014017814A8 (sr)
CA (1)	CA2862222A1 (sr)
CY (1)	CY1121335T1 (sr)
DK (1)	DK2804878T3 (sr)
ES (1)	ES2698606T3 (sr)
HK (1)	HK1208684A1 (sr)
HR (1)	HRP20181874T1 (sr)
HU (1)	HUE041900T2 (sr)
IL (2)	IL233694A0 (sr)
LT (1)	LT2804878T (sr)
MX (1)	MX359854B (sr)
PL (1)	PL2804878T3 (sr)
PT (1)	PT2804878T (sr)
RS (1)	RS58141B1 (sr)
RU (1)	RU2663141C2 (sr)
SG (2)	SG11201406762QA (sr)
SI (1)	SI2804878T1 (sr)
TW (1)	TWI596112B (sr)
UY (1)	UY34582A (sr)
WO (1)	WO2013109974A2 (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
MA40526A (fr)	2014-08-22	2017-06-28	Sorrento Therapeutics Inc	Protéines de fixation antigénique fixant le cxcr3
WO2017075432A2 (en) *	2015-10-29	2017-05-04	Alector Llc	Anti-siglec-9 antibodies and methods of use thereof
WO2017205377A2 (en) *	2016-05-23	2017-11-30	New York University	Compositions and methods for antibodies targeting staphylococcal leukotoxins
KR20190095942A (ko) *	2016-12-22	2019-08-16	사노피	백반증의 치료를 위한 항-인간 cxcr3 항체
US20180244787A1 (en)	2016-12-22	2018-08-30	Sanofi	Anti-human cxcr3 antibodies for treatment of vitiligo
UY37544A (es)	2016-12-22	2018-07-31	Sanofi Sa	Anticuerpos humanizados contra cxcr3 con actividad mermadora y métodos de uso de los mismos
EP3752134B1 (en) *	2018-02-16	2024-12-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating vitiligo
CN113573728A (zh)	2018-11-14	2021-10-29	安驰肿瘤公司	治疗性SIRPα抗体
TWI859420B (zh)	2020-02-26	2024-10-21	美商維爾生物科技股份有限公司	抗sars-cov-2抗體及使用其之方法
US20230279108A1 (en) *	2020-04-30	2023-09-07	Arch Oncology, Inc.	Therapeutic sirp-alpha antibodies
US20240101673A1 (en)	2021-02-03	2024-03-28	Mozart Therapeutics, Inc.	Binding agents and methods of using the same
AU2022229356A1 (en) *	2021-03-02	2023-08-10	Novarock Biotherapeutics, Ltd.	Antibodies against claudin-6 and uses thereof
KR20240043784A (ko) *	2021-08-09	2024-04-03	메르크 파텐트 게엠베하	염증유발성 시토카인의 방출로부터 t 세포-매개 종양 세포독성을 디커플링시키는 단백질
WO2023076876A1 (en)	2021-10-26	2023-05-04	Mozart Therapeutics, Inc.	Modulation of immune responses to viral vectors
WO2024052445A1 (en)	2022-09-09	2024-03-14	Idorsia Pharmaceuticals Ltd	Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US565332A (en)		1896-08-04		Toy for making soap-bubbles
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP1186660A3 (fr)	1985-03-30	2002-03-20	KAUFFMAN, Stuart A.	Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5763192A (en)	1986-11-20	1998-06-09	Ixsys, Incorporated	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
EP0571613B1 (en)	1991-12-13	2003-09-17	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ES2162823T5 (es)	1992-08-21	2010-08-09	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
AU6796094A (en)	1993-04-29	1994-11-21	Raymond Hamers	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
JP2826272B2 (ja)	1993-10-26	1998-11-18	タイガースポリマー株式会社	中空樹脂成形品の製造装置及び製造方法
US5565352A (en)	1993-11-24	1996-10-15	Arch Development Corporation	Deubiquitinating enzyme: compositions and methods
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
DE69737656T2 (de) *	1996-09-10	2008-01-03	Theodor Kocher Institut	Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US6140064A (en) *	1996-09-10	2000-10-31	Theodor-Kocher Institute	Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
WO2001072334A2 (en) *	2000-03-27	2001-10-04	Corixa Corporation	Methods for treating disease with antibodies to cxcr3
US7118915B2 (en)	2001-09-27	2006-10-10	Pieris Proteolab Ag	Muteins of apolipoprotein D
KR20060106631A (ko) *	2003-06-30	2006-10-12	바이오-테크널러지 제너럴 (이스라엘) 리미티드	항체 및 이의 용도
EP1631315B1 (en)	2003-09-24	2014-07-30	Millennium Pharmaceuticals, Inc.	Antibodies which bind human cxcr3
ES2384176T3 (es) *	2004-03-23	2012-07-02	Eli Lilly & Company	Anticuerpos anti-miostatina
JP2008509666A (ja)	2004-08-11	2008-04-03	トルビオン・ファーマシューティカルズ・インコーポレイテッド	結合ドメイン融合タンパク質
EP2007808A4 (en)	2006-04-14	2010-07-21	Trubion Pharmaceuticals Inc	BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
WO2008094942A2 (en)	2007-02-01	2008-08-07	Teva Biopharmaceuticals Usa, Inc.	Humanized antibodies against cxcr3
BRPI0815983A2 (pt)	2007-08-29	2018-05-22	Sanofi Aventis	anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
WO2010056907A2 (en)	2008-11-12	2010-05-20	The Scripps Research Institute	Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) *	2009-03-12	2010-09-16	Rappaport Family Institute For Research In The Medical Sciences	Soluble compositions for the treatment of cxcr3-ligand associated diseases
CA2789963C (en) *	2010-02-26	2019-09-03	Bioarctic Neuroscience Ab	Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

2013
- 2013-01-18 RS RS20181422A patent/RS58141B1/sr unknown
- 2013-01-18 AU AU2013209492A patent/AU2013209492B2/en not_active Ceased
- 2013-01-18 PT PT13702548T patent/PT2804878T/pt unknown
- 2013-01-18 LT LTEP13702548.2T patent/LT2804878T/lt unknown
- 2013-01-18 WO PCT/US2013/022280 patent/WO2013109974A2/en active Application Filing
- 2013-01-18 US US13/745,377 patent/US8865870B2/en not_active Expired - Fee Related
- 2013-01-18 SG SG11201406762QA patent/SG11201406762QA/en unknown
- 2013-01-18 HU HUE13702548A patent/HUE041900T2/hu unknown
- 2013-01-18 KR KR1020147023225A patent/KR102073034B1/ko active IP Right Grant
- 2013-01-18 PL PL13702548T patent/PL2804878T3/pl unknown
- 2013-01-18 DK DK13702548.2T patent/DK2804878T3/en active
- 2013-01-18 SG SG10201700735PA patent/SG10201700735PA/en unknown
- 2013-01-18 JP JP2014553482A patent/JP6352812B6/ja not_active Expired - Fee Related
- 2013-01-18 SI SI201331249T patent/SI2804878T1/sl unknown
- 2013-01-18 CN CN201380015401.8A patent/CN104507967B/zh not_active Expired - Fee Related
- 2013-01-18 ES ES13702548T patent/ES2698606T3/es active Active
- 2013-01-18 CA CA2862222A patent/CA2862222A1/en not_active Abandoned
- 2013-01-18 RU RU2014134043A patent/RU2663141C2/ru active
- 2013-01-18 BR BR112014017814A patent/BR112014017814A8/pt not_active Application Discontinuation
- 2013-01-18 MX MX2014008728A patent/MX359854B/es active IP Right Grant
- 2013-01-18 EP EP13702548.2A patent/EP2804878B1/en active Active
- 2013-01-18 KR KR1020207002561A patent/KR20200014441A/ko not_active Application Discontinuation
- 2013-01-21 TW TW102102282A patent/TWI596112B/zh not_active IP Right Cessation
- 2013-01-21 UY UY0001034582A patent/UY34582A/es not_active Application Discontinuation
- 2013-01-21 AR ARP130100184A patent/AR090056A1/es unknown
2014
- 2014-07-17 IL IL233694A patent/IL233694A0/en unknown
- 2014-09-08 US US14/480,052 patent/US9765144B2/en active Active
2015
- 2015-09-23 HK HK15109327.8A patent/HK1208684A1/xx not_active IP Right Cessation
2017
- 2017-08-04 US US15/669,556 patent/US20180086838A1/en not_active Abandoned
2018
- 2018-05-07 JP JP2018089004A patent/JP6646100B2/ja not_active Expired - Fee Related
- 2018-09-14 US US16/132,333 patent/US20190119391A1/en not_active Abandoned
- 2018-11-08 HR HRP20181874TT patent/HRP20181874T1/hr unknown
- 2018-11-22 CY CY20181101236T patent/CY1121335T1/el unknown
2019
- 2019-12-24 IL IL271697A patent/IL271697A/en unknown
2020
- 2020-01-08 JP JP2020001152A patent/JP2020072715A/ja active Pending

Also Published As

Publication number	Publication date
US20130251733A1 (en)	2013-09-26
SG10201700735PA (en)	2017-02-27
IL233694A0 (en)	2014-09-30
US20140377806A1 (en)	2014-12-25
PT2804878T (pt)	2018-11-29
JP2018166506A (ja)	2018-11-01
TW201335188A (zh)	2013-09-01
JP2020072715A (ja)	2020-05-14
SI2804878T1 (sl)	2018-12-31
HRP20181874T1 (hr)	2019-01-11
SG11201406762QA (en)	2014-11-27
US8865870B2 (en)	2014-10-21
WO2013109974A2 (en)	2013-07-25
PL2804878T3 (pl)	2019-03-29
DK2804878T3 (en)	2018-12-17
JP6646100B2 (ja)	2020-02-14
RU2014134043A (ru)	2016-03-20
US20190119391A1 (en)	2019-04-25
RU2663141C2 (ru)	2018-08-01
AU2013209492A1 (en)	2014-08-14
ES2698606T3 (es)	2019-02-05
UY34582A (es)	2013-09-02
EP2804878B1 (en)	2018-08-22
MX359854B (es)	2018-10-12
LT2804878T (lt)	2018-12-10
EP2804878A2 (en)	2014-11-26
HK1208684A1 (en)	2016-03-11
BR112014017814A8 (pt)	2017-07-11
KR20140116525A (ko)	2014-10-02
TWI596112B (zh)	2017-08-21
BR112014017814A2 (sr)	2017-06-20
KR102073034B1 (ko)	2020-02-05
MX2014008728A (es)	2015-07-06
JP2015506945A (ja)	2015-03-05
KR20200014441A (ko)	2020-02-10
CN104507967B (zh)	2018-10-12
CA2862222A1 (en)	2013-07-25
CN104507967A (zh)	2015-04-08
AR090056A1 (es)	2014-10-15
US9765144B2 (en)	2017-09-19
CY1121335T1 (el)	2020-05-29
AU2013209492B2 (en)	2018-02-08
IL271697A (en)	2020-02-27
WO2013109974A3 (en)	2013-11-07
JP6352812B2 (ja)	2018-07-04
JP6352812B6 (ja)	2018-08-08
US20180086838A1 (en)	2018-03-29
HUE041900T2 (hu)	2019-06-28

Publication	Publication Date	Title
IL293362B1 (en)	2023-04-01	Broad-spectrum neutralizing antibodies against the AIDS virus
IL271697A (en)	2020-02-27	Antibodies against CXCR3
IL264558A (en)	2019-02-28	Anti–il–23p19 antibodies
HK1204571A1 (en)	2015-11-27	Protease-regulated antibodies
ZA201407509B (en)	2016-02-24	Anti-fcrn antibodies
HK1210192A1 (en)	2016-04-15	Anti-siglec-15 antibodies siglec-15
HK1210186A1 (en)	2016-04-15	Anti-h7cr antibodies h7cr
PL2935330T3 (pl)	2019-11-29	Przeciwciała przeciw notch3
EP2804876A4 (en)	2016-02-24	NEW ANTIBODIES
IL235188A0 (en)	2014-12-31	Antibodies against c-pdgf
GB201209584D0 (en)	2012-07-11	Modified antibodies